phage therapy is the use of bacteriophages to kill pathogenic bacterial cells. Bacteriophages are bacterial parasites that invade bacterial cells and engulf them like blue whale fish kills euphausiids and copepodsand in sea .
Phage therapy (PT) is also called bacteriophage therapy. It uses viruses to treat bacterial infections. Bacterial viruses are called phages or bacteriophages. They only attack bacteria; phages are harmless to people, animals, and plants. Bacteriophages are the natural enemies of bacteria.
Phage therapy (PT) is also called bacteriophage therapy. It uses viruses to treat bacterial infections. Bacterial viruses are called phages or bacteriophages. They only attack bacteria; phages are harmless to people, animals, and plants. Bacteriophages are the natural enemies of bacteria.
CRISPR (clustered regularly interspaced short palindromic repeats) is a family of DNA sequences found within the genomes of prokaryotic organisms such as bacteria and archaea. These sequences are derived from DNA fragments of bacteriophages that have previously infected the prokaryote and are used to detect and destroy DNA from similar phages during subsequent infections. Hence these sequences play a key role in the antiviral defense system of prokaryotes.
Cas9 (CRISPR-associated protein 9) is an enzyme that uses CRISPR sequences as a guide to recognize and cleave specific strands of DNA that are complementary to the CRISPR sequence. Cas9 enzymes together with CRISPR sequences form the basis of a technology known as CRISPR-Cas9 that can be used to edit genes within organisms.This editing process has a wide variety of applications including basic biological research, development of biotechnology products, and treatment of diseases.
The CRISPR-Cas system is a prokaryotic immune system that confers resistance to foreign genetic elements such as those present within plasmids and phages that provides a form of acquired immunity. RNA harboring the spacer sequence helps Cas (CRISPR-associated) proteins recognize and cut foreign pathogenic DNA. Other RNA-guided Cas proteins cut foreign RNA. CRISPR are found in approximately 50% of sequenced bacterial genomes and nearly 90% of sequenced archaea.
A bacteriophage (informally, phage) is a virus that infects and replicates within a bacterium. The term is derived from "bacteria" and the Greek (phagein), "to devour". Bacteriophages are composed of proteins that encapsulate a DNA or RNA genome, and may have relatively simple or elaborate structures. Their genomes may encode as few as four genes, and as many as hundreds of genes. Phages replicate within the bacterium following the injection of their genome into its cytoplasm. Bacteriophages are among the most common and diverse entities in the biosphere.
Phages are widely distributed in locations populated by bacterial hosts, such as soil or the intestines of animals. One of the densest natural sources for phages and other viruses is sea water, where up to 9×108 virions per milliliter have been found in microbial mats at the surface,] and up to 70% of marine bacteria may be infected by phages. They have been used for over 90 years as an alternative to antibiotics in the former Soviet Union and Central Europe, as well as in France. They are seen as a possible therapy against multi-drug-resistant strains of many bacteria (see phage therapy). Nevertheless, phages of Inoviridae have been shown to complicate biofilms involved in pneumonia and cystic fibrosis, shelter the bacteria from drugs meant to eradicate disease and promote persistent infection
Alan Lesniewicz Memorial Lecture at UIC - July 2015Cassandra Quave
This is the keynote lecture given at the University of Illinois at Chicago Garden Walk event in the department of Pharmacognosy. The objectives of the talk were:
·Discuss the role of medical ethnobotany in drug discovery efforts
·Explore state-of-the-art research techniques that examine the activity of botanical natural products with next generation antibiotic discovery efforts focused on “alternative targets”, such as bacterial communication systems
·Provide examples of current research underway by her group both in the field (especially through fieldwork in the Mediterranean) and the lab (natural product research on multidrug resistant bacteria).
CRISPR (clustered regularly interspaced short palindromic repeats) is a family of DNA sequences found within the genomes of prokaryotic organisms such as bacteria and archaea. These sequences are derived from DNA fragments of bacteriophages that have previously infected the prokaryote and are used to detect and destroy DNA from similar phages during subsequent infections. Hence these sequences play a key role in the antiviral defense system of prokaryotes.
Cas9 (CRISPR-associated protein 9) is an enzyme that uses CRISPR sequences as a guide to recognize and cleave specific strands of DNA that are complementary to the CRISPR sequence. Cas9 enzymes together with CRISPR sequences form the basis of a technology known as CRISPR-Cas9 that can be used to edit genes within organisms.This editing process has a wide variety of applications including basic biological research, development of biotechnology products, and treatment of diseases.
The CRISPR-Cas system is a prokaryotic immune system that confers resistance to foreign genetic elements such as those present within plasmids and phages that provides a form of acquired immunity. RNA harboring the spacer sequence helps Cas (CRISPR-associated) proteins recognize and cut foreign pathogenic DNA. Other RNA-guided Cas proteins cut foreign RNA. CRISPR are found in approximately 50% of sequenced bacterial genomes and nearly 90% of sequenced archaea.
A bacteriophage (informally, phage) is a virus that infects and replicates within a bacterium. The term is derived from "bacteria" and the Greek (phagein), "to devour". Bacteriophages are composed of proteins that encapsulate a DNA or RNA genome, and may have relatively simple or elaborate structures. Their genomes may encode as few as four genes, and as many as hundreds of genes. Phages replicate within the bacterium following the injection of their genome into its cytoplasm. Bacteriophages are among the most common and diverse entities in the biosphere.
Phages are widely distributed in locations populated by bacterial hosts, such as soil or the intestines of animals. One of the densest natural sources for phages and other viruses is sea water, where up to 9×108 virions per milliliter have been found in microbial mats at the surface,] and up to 70% of marine bacteria may be infected by phages. They have been used for over 90 years as an alternative to antibiotics in the former Soviet Union and Central Europe, as well as in France. They are seen as a possible therapy against multi-drug-resistant strains of many bacteria (see phage therapy). Nevertheless, phages of Inoviridae have been shown to complicate biofilms involved in pneumonia and cystic fibrosis, shelter the bacteria from drugs meant to eradicate disease and promote persistent infection
Alan Lesniewicz Memorial Lecture at UIC - July 2015Cassandra Quave
This is the keynote lecture given at the University of Illinois at Chicago Garden Walk event in the department of Pharmacognosy. The objectives of the talk were:
·Discuss the role of medical ethnobotany in drug discovery efforts
·Explore state-of-the-art research techniques that examine the activity of botanical natural products with next generation antibiotic discovery efforts focused on “alternative targets”, such as bacterial communication systems
·Provide examples of current research underway by her group both in the field (especially through fieldwork in the Mediterranean) and the lab (natural product research on multidrug resistant bacteria).
About Pherecydes Pharma
Pherecydes Pharma SA specializes in the research and development of lytic bacteriophages
(or phages) for both therapeutic and diagnostic applications. The company provides
innovative and adaptable solutions to combat multi-resistant bacteria, through developing
mixtures of natural phages and their accelerated in vitro evolution. Pherecydes Pharma is
the only company currently that has been able to harness this evolution technology, allowing
a head start on any given bacterium.
Due to the unique knowledge of the company in the characterization and rapid isolation of
natural lytic phages, Pherecydes Pharma has developed a large bank of bacteriophage
mixtures for combating infections that are resistant to antibiotics, which have steadily
increased in number since the 1980s. In particular, it possesses the world’s largest
collection of phages against Escherichia coli and is also working on Pseudomonas and
Staphylococci, three bacteria that alone represent over 50% of known infections in
industrialized countries.
Introduction to Bacteriophage
Classification
Phage Life Cycle
Where we can find phages?
Desirable properties of phages used as biocontrol agents in foods
Bacteriophages for biocontrol of pathogens in food
Some reviews on Bacteriophage in food safety
Large Scale Production and Purification Strategy
Bacteriophages in Detection
Advantages of Phage
Challenges in Bacteriophage and Measures to control
Obligate intracellular parasites that multiply inside bacteria by making use of some or all of the host biosynthetic machinery
Bacteriophage and its Applications in Foodrasha mohamed
Introduction to Bacteriophage
Classification
Phage Life Cycle
Where we can find phages?
Desirable properties of phages used as biocontrol agents in foods
Bacteriophages for biocontrol of pathogens in food
Some reviews on Bacteriophage in food safety
Large Scale Production and Purification Strategy
Bacteriophages in Detection
Advantages of Phage
Challenges in Bacteriophage and Measures to control
Obligate intracellular parasites that multiply inside bacteria by making use of some or all of the host biosynthetic machinery
Isolation, Characterization, and Antibiotics Resistance Profile of Staphyloco...AdeyemiKayode2
Isolation, Characterization, and Antibiotics Resistance Profile of Staphylococci from Indoor Air of the Students’ Halls of Residence at the Obafemi Awolowo University, Ile Ife, Nigeria.
What next for prevention of pneumococcal disease in light of serotype replacement? Is there a pathway to licensure for novel pneumococcal vaccines?
https://www.meningitis.org/mrf-conference-2017
Global germplasm collections: sure benefits without seedborne diseasesCIAT
The Genetic Resources Program is the germplasm bank of CIAT which conserves the collections of bean and tropical forage seeds, and the collection of cassava "in vitro" for a total of approximately 67,500 different accessions. The conservation of these collections allows the benefit of the distribution of germplasm of approximately 6,000 samples of genetic material per year, at national and international level. To minimize the risks associated with the movement of germplasm, especially the transport of pathogens of quarantine interest, it is required a process of laboratory tests certifying the plant quality. This process is carried out in the Germplasm Health Laboratory of the GRP, where also research is developed to improve the effectiveness of the detection, testing reliability and efficiency of operations.
Candidia Species Commonly (Opportunistic human Pathogens)
C.albicans
C.glabata
C.guilliermandii
C.krusei
C.lusitaniae
C.parapsilosis
C.tropicalis
Candiia Species Uncommonly: 18 species
Probiotics are useful microorganisms to fight against pathogenic bacteria in human gut . Commercially bacteria and fungus are being used as probiotic organisms
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
3. INTRODUCTION
Phage therapy :- Use of bacteriophage to
treat pathogenic bacterial infection
Multidrug resistant bacteria –challenging to
modern medicine
There is need of alternative to conventional
antibiotics
Phage therapy - An Old Idea Re-Emerging
10. Phage Sources
Omnipresent
Like bacteria, bacteriophages are found
everywhere
In water the probable ratio of phages to
bacteria is 10 :1
Phages have been found in the deserts as
well as simple top soil fields
15. STORAGE
Different preservation methods, such as storage of crude or
purified phage lysates In 40% glycerol at 4◦c freezing or at
−80 °C or in liquid nitrogen, and finally storage of dried or
lyophilized phages
18. Protein receptors
OmpA -for phage k3
OmpC –For phage T4,Hy2
OmpF –For Phage T2
Ton A –For phage T 5
LamB –For lambda phage
19. LPS RECEPTORS
Two types of LPS receptors
Smooth receptor-Lipid A ,core, O chain
shows narrow range of specificity
Rough receptor-lipid A ,Core
LPS of Salmonella for phage P22
20. How phage acts on bacterial cell wall?
Holins
Perforate in cell wall
Lysins
Hydrolytic enzymes produced by bacteriophages in
order to cleave host's cell wall during final stage of
lytic cycle
26. EXPERIMENTAL PHAGE THERAPY AGAINST
STAPHYLOCOCCUS AUREUS IN MICE
This study describes a bacteriophage active
against Staphylococcus aureus, including
methicillin-resistant staphylococcal strains.
When inoculated into mice simultaneously with S.
aureus A170 (108 CFU/mouse), then 97% of the
mice recovered
Rosanna et al; antimicrob. Agents chemother ‘may
2007
27.
28. PHAGE THERAPY OF PSEUDOMONAS
AERUGINOSA INFECTION IN A MOUSE BURN
WOUND MODEL
31. BACTERIOPHAGES AS BIOCONTROL AGENTS OF
FOOD PATHOGENS Pub.22 APRIL 2011
Phage research is focused on phages infecting
such pathogenic bacteria.
In terms of food pathogens,phages against
Campylobacter jejuni, Salmonella enterica Listeria
monocytogenes and Streptococcus suis have been
isolated and characterized,and each of these clear
the therapeutic use of these phages
33. Catheters were exposed to a 10 log PFU PER ml
lysate of P. aeruginosa phage M4 for 2 h at 37°C
The mean viable biofilm count on untreated
catheters was 6.87 log
The pretreatment of catheters with phage reduced
this value to 4.03 log CFU
35. Advantages Over antibiotics
antibiotics Phage therapy
Specificity Effecting more than
targeted oraganisms
Species or strain specific
Side effects Allergic reactions
Intestinal disorder etc.
No or minor side effects
resistance Occurs and not limited to
targeted organisms
Occurs but phage can co
–evolve with host
production Time consuming and
expensive
Rapid
38. Problem 2:- Bacterial debris present in
the phage preparation
Solution :-Modern technology allows density
centrifugation and other methods of
purification.
40. PROBLEM :-ANTI-PHAGE ANTIBODIES
Solution
In treating chronic infections it may be possible to
administer a higher dose of phage, to compensate
for those that are Cleared by interaction with
neutralizing antibodies.
.
41. CONTROVERSIES
Phages are viruses ,so they can harm genetic
make up of human beings by mutation or by any
other mechanism
In some cases Bacteria can show resistance
against phages.
42. CURRENT STATUS OF HUMAN PHAGE THERAPY
Still phage therapy Approved in
Russia ,
Poland
Georgia
43. PHAGOBURN PROJECT
It is a European Research & Development (R&D)
project funded by the European Commission
It aims at evaluating phage therapy for the
treatment of burn wounds infected with bacteria
Escherichia coli and Pseudomonas aeruginosa.
46. FUTURE PROSPECTS
Infectious disease experts have warned that there is
now a compelling need to develop totally new
classes of antibacterial agents, ones that cannot be
resisted by the same genes that render bacteria
resistant to antibiotics.
47. CONCLUSION
Multidrug-resistant bacteria have opened a second
window for phage therapy. Modern innovations,
combined with careful scientific methodology, can
enhance mankind’s ability to make it work this time
around.
Phage therapy can then serve as a stand-alone
therapy for infections that are fully resistant.
It will also then be able to serve as a co-therapeutic
agent for infections that are still susceptible to
antibiotics, by helping to prevent the emergence of
bacterial mutants against either agent.
